Key Takeaways
- Eli Lilly (LLY) and Novo Nordisk (NVO) are nearing landmark deals with the U.S. government to significantly expand access to their leading obesity drugs, Zepbound and Wegovy, potentially offering treatments for Medicare patients at $149-$299 per month and accelerating FDA review for new therapies.
- The Trump administration is poised to announce major international trade agreements, including an $8 billion+ order for up to 22 Boeing 787 Dreamliners by Uzbekistan Airways, a deal projected to support nearly 35,000 U.S. jobs.
- Novo Nordisk's investigational obesity drug, Cagrisema, demonstrated a nearly 70% reduction in a key inflammatory marker associated with increased cardiovascular risk and a 10.9 mmHg reduction in systolic blood pressure in its Phase 3 REDEFINE 1 trial.
- Ford (F) is reportedly halting production of its F-150 Lightning electric pickup for several weeks due to softening demand, following a $1.2 billion quarterly loss in its EV division.
- OpenAI CEO Sam Altman is actively seeking "trillions" of dollars to fund a global network of AI chip fabrication plants, while U.S. crude oil futures settled at $59.43/bbl, down 0.29%.
Pharmaceutical Sector Sees Major Developments
The pharmaceutical industry is buzzing with significant news, particularly concerning obesity treatments. Eli Lilly (LLY) and Novo Nordisk (NVO), key players in the weight-loss drug market, are reportedly close to finalizing deals with the Trump administration to broaden access to their highly sought-after medications. These agreements could see the lowest doses of Eli Lilly's Zepbound (tirzepatide) offered for $299 per month and its experimental oral drug orforglipron for $149 per month through the TrumpRx initiative for Medicare patients. The negotiations also involve a push for priority FDA approval for Lilly's new treatments.
Meanwhile, Novo Nordisk (NVO) has announced positive results for its investigational injectable combination treatment, Cagrisema. New post hoc analyses from the Phase 3 REDEFINE 1 trial revealed a nearly 70% reduction in a key inflammatory marker linked to increased cardiovascular risk. The drug also showed a 10.9 mmHg reduction in systolic blood pressure over 68 weeks, enabling approximately 40% of patients on blood pressure medication to reduce or discontinue their treatment. These findings were presented at ObesityWeek, highlighting Cagrisema's potential to address both weight and cardiovascular health in adults with overweight or obesity.
Aerospace and Trade: Boeing Secures Central Asian Deals
The Trump administration is preparing to announce substantial international trade agreements, with Boeing (BA) at the forefront. Uzbekistan Airways has committed to purchasing up to 22 Boeing 787 Dreamliners (14 firm orders with options for 8 more) in a deal valued at over $8 billion. This agreement, hailed by the U.S. Commerce Department as the "largest commercial aircraft agreement of its kind in Central Asia," is expected to generate nearly 35,000 U.S. jobs. Additionally, Kazakhstan has finalized a $4.2 billion deal to acquire 300 freight locomotives from Wabtec Corporation, further solidifying U.S. trade ties in the region.
Automotive Shift: Ford Reconsiders EV Strategy
In the automotive sector, Ford (F) is reportedly adjusting its electric vehicle production strategy. The company is expected to halt production of its F-150 Lightning electric pickup truck for several weeks, from mid-November through January 6, citing softening demand. This move follows a challenging period for Ford's EV division, Ford Model e, which recorded a $1.2 billion loss in the third quarter, with revenue declining by a third year-over-year. Production of the F-150 Lightning had already been scaled back earlier in the year, and Ford has also halved its 2024 production targets for the electric truck.
Tech and Energy Updates
OpenAI CEO Sam Altman is reportedly embarking on an ambitious fundraising initiative, seeking "trillions" of dollars to establish a global network of AI chip fabrication plants. Altman has engaged with various investors, including those from the UAE and Softbank, as well as major chipmakers like TSMC, to address the critical scarcity of AI chips. He has discussed securing loan guarantees for these chip fabs, but not for OpenAI's own datacenters, with the entire venture requiring U.S. government approval due to potential national security and antitrust implications.
In energy markets, U.S. crude oil futures settled at $59.43 per barrel, marking a slight decrease of 17 cents or 0.29%.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.